PRLD on XNAS, Health Care, Prelude Therapeutics Incorporated, job postings
Measures activity, not value. Not investment advice.
Revenue rose 105% to $21.6M while short interest is 9.9 times last year's level.
GoodInstitutional holders rose 18%, from 76 filers to 90
WatchShares up 102% in 12 months but down 24% in 6 months
Written by AI from the data on this page, 22 Nov 2026. Not investment advice.
Profile and fundamentals
From its SEC filings, 12 months to 30 Sep 2026
Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.
expected around 9 Mar 2027 (an estimate: a year ago it reported on 10 Mar 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $5.6M, net loss $12.5M.
31 Dec 2021RevenueNet incomeNet losstallest bar $34.7M30 Sep 2026
See the numbers
Quarter to
Revenue
Net income
30 Sep 2026
$5.6M
-$12.5M
30 Jun 2026
$5.7M
-$13.9M
31 Mar 2026
$4.6M
-$10.4M
31 Dec 2025
$5.6M
-$16.5M
30 Sep 2025
$6.5M
-$19.7M
30 Jun 2025
$0
-$31.2M
31 Mar 2025
$0
-$32.1M
31 Dec 2024
$4.0M
-$28.7M
30 Sep 2024
$3.0M
-$32.3M
30 Jun 2024
–
-$34.7M
31 Mar 2024
–
-$31.4M
31 Dec 2023
–
-$33.1M
30 Sep 2023
–
-$30.6M
30 Jun 2023
–
-$30.4M
31 Mar 2023
–
-$27.7M
31 Dec 2022
–
-$28.6M
30 Sep 2022
–
-$30.0M
30 Jun 2022
–
-$27.4M
31 Mar 2022
–
-$29.5M
31 Dec 2021
–
-$32.8M
Fundamentals, 12 months to 30 Sep 2026
Measure
Latest
Year before
Peer median
RevenueiSales over the last 12 months reported.
$21.6M
$10.5M
Revenue growthiRevenue of the last 12 months compared with the 12 months before.
+105%
+11%
Net incomeiProfit after all costs and taxes over the last 12 months reported. Negative is a loss.
-$53.3M
-$111.8M
EPS (diluted)iEarnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split).
-$0.59
-$1.47
Gross marginiWhat is left of each dollar of sales after the direct cost of making the product or service.
–
–
73.2%
Operating marginiOperating income as a share of sales: profit from the business before interest and taxes.
-284%
–
-25.0%
Net marginiNet income as a share of sales: what the owners keep of each dollar sold.
-247%
–
-18.2%
Return on equityiNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money.
-58.4%
-58.8%
Free cash flowiCash from operations minus capital spending over the last 12 months: cash the business produced.
–
–
CashiCash, cash equivalents and short-term investments on the latest balance sheet.
$140.0M
$55.0M
DebtiShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted.
$0
$0
Net debtiDebt minus cash. Negative means the company holds more cash than it owes (net cash).
-$140.0M (net cash)
-$55.0M
Debt to equityiDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative.
0.0
0.0
Book value per shareiShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding.
$1.55
P/EiPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss.
loss
19.3
P/SiPrice to sales: market cap divided by revenue of the last 12 months.
12.0
5.0
EV/SalesiEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months.
5.5
5.0
P/BiPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative.
2.1
2.0
Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.
Peers nearest by market cap, its own industry first
Insider Buy/Sell iShares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.
–
No data for this company
Institutional holders iThe number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.
+18%
90 13F filers vs 76
Institutional ownership iShares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.
72%
57.8M shares held by 13F filers (30 Sep 2026) of 80.1M outstanding (11 Nov 2026)
Short interest iShares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.
5.2%
4.2M shares sold short (30 Oct 2026) of 80.1M outstanding (11 Nov 2026)
Days to cover iShort interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.
9.1
4.2M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it
Short interest change iHow the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.
-18%
5.1M shares sold short in the report before, 4.2M on 30 Oct 2026
Short sale volume iShare of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.
60%
60% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 48%
Open jobs iJob postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.
–
We do not track this company's careers site yet.
Open jobs change iHow the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.
–
We do not track this company's careers site yet.
Employees iTotal staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.
–
No headcount in its annual reports in our data.
Visa hiring (foreign workers) iApplications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.
–
No data for this company
Revenue growth iSales in the latest reported quarter compared with the same quarter a year earlier.
–
No data for this company
Capital spending iMoney spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.
–
No data for this company
Federal contracts iMoney the US government committed to the company in contracts and grants over the last 12 months.
–
No data for this company
Lobbying iWhat the company reported spending on federal lobbying over the last four quarters.
–
No data for this company
Layoff notices iWorkers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).
–
No data for this company
News (7d) iArticles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.
9
9 articles in the last 7 days; its usual week has 1 (the median of the 26 weeks before).
News vs usual iArticles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.
9.0×
9 articles in the last 7 days; its usual week has 1.
Unusual now sharp changes in the last 90 days, compared with its own past
Short interest 5.1M, 9.9× a year earlier
Price $3.23 on 20 Nov 2026, +102% over 12 months (12-month range $1.34 to $6.63)
Sharp change
8-K and other filings
Insider net buying (open market). Insiders bought a net $12.5M in the last 12 months (the 12 months before: $874K).H-1B/E-3 applications certified. H-1B/E-3 applications certified: 0 published in the last 12 months, -100% on the 12 months before.Revenue per quarter. Revenue $5.6M in the latest quarter, -13% on a year earlier.Capital spending per quarter. Capital spending $35K in the latest quarter.Institutional holders (13F filers). 90 13F filers reported holding it in the latest 13F quarter, +100% on a year earlier.
Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: federal obligations, lobbying spend, workers in warn layoff notices.
Two or more unrelated kinds of records unusual within 30 days
27 Dec 2024confirmed
Confirmed across sources Insiders and Short interest and volume
Prelude Therapeutics(PRLD): had 3 insiders buy $208K of its shares on the open market within 30 days (3 filings), while it had 3.1M shares sold short in the 31 Jan 2025 report, 6.0× the same report last year. Two unrelated kinds of activity within 77 days.
Short interest and volume: Short interest spike, became public on 27 Nov 2024
Short interest and volume: Short interest spike, became public on 11 Dec 2024
Insiders: Clustered insider buying, became public on 27 Dec 2024
Short interest and volume: Short interest spike, became public on 25 Dec 2024
Short interest and volume: Short interest spike, became public on 14 Jan 2025
Short interest and volume: Short interest spike, became public on 28 Jan 2025
Short interest and volume: Short interest spike, became public on 12 Feb 2025
The 31 Jan 2025 report against the 24 reports before it.
this reportearliernormal: 707KSee the evidence (7 changes)
Short interest and volume: Short interest spike became public on 27 Nov 2024
Prelude Therapeutics had 2.9M shares sold short in the 15 Nov 2024 report, 3.6× the same report last year.
This period
2.9M (the 15 Nov 2024 report)
Normal report (median of 24 earlier)
626K
Typical spread (median absolute deviation)
109K
How far from its usual level
+14.0
Same report last year
804K
History used
1,507 days
the 15 Nov 2024 report24 earlier reportsnormal: 626K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 11 Dec 2024
Prelude Therapeutics had 3.1M shares sold short in the 29 Nov 2024 report, 4.1× the same report last year.
This period
3.1M (the 29 Nov 2024 report)
Normal report (median of 24 earlier)
626K
Typical spread (median absolute deviation)
109K
How far from its usual level
+15.0
Same report last year
741K
History used
1,521 days
the 29 Nov 2024 report24 earlier reportsnormal: 626K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.
Short interest and volume: Short interest spike became public on 25 Dec 2024
Prelude Therapeutics had 3.3M shares sold short in the 13 Dec 2024 report, 4.8× the same report last year.
This period
3.3M (the 13 Dec 2024 report)
Normal report (median of 24 earlier)
626K
Typical spread (median absolute deviation)
113K
How far from its usual level
+15.7
Same report last year
680K
History used
1,535 days
the 13 Dec 2024 report24 earlier reportsnormal: 626K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 14 Jan 2025
Prelude Therapeutics had 3.4M shares sold short in the 31 Dec 2024 report, 7.6× the same report last year.
This period
3.4M (the 31 Dec 2024 report)
Normal report (median of 24 earlier)
626K
Typical spread (median absolute deviation)
134K
How far from its usual level
+13.9
Same report last year
447K
History used
1,553 days
the 31 Dec 2024 report24 earlier reportsnormal: 626K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 28 Jan 2025
Prelude Therapeutics had 3.1M shares sold short in the 15 Jan 2025 report, 6.9× the same report last year.
This period
3.1M (the 15 Jan 2025 report)
Normal report (median of 24 earlier)
637K
Typical spread (median absolute deviation)
134K
How far from its usual level
+12.5
Same report last year
451K
History used
1,568 days
the 15 Jan 2025 report24 earlier reportsnormal: 637K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 12 Feb 2025
Prelude Therapeutics had 3.1M shares sold short in the 31 Jan 2025 report, 6.0× the same report last year.
This period
3.1M (the 31 Jan 2025 report)
Normal report (median of 24 earlier)
707K
Typical spread (median absolute deviation)
194K
How far from its usual level
+8.5
Same report last year
522K
History used
1,584 days
the 31 Jan 2025 report24 earlier reportsnormal: 707K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
Timeline
Changes and notable records, by the date each became public
27 Oct 2026Short interest and volume change
had 5.1M shares sold short in the 15 Oct 2026 report, 9.9× the same report last year.
Same report last year: 515K; its normal report is 2.0M.
See the evidence
This period
5.1M (the 15 Oct 2026 report)
Normal report (median of 24 earlier)
2.0M
Typical spread (median absolute deviation)
587K
How far from its usual level
+3.6
Same report last year
515K
History used
2,206 days
the 15 Oct 2026 report24 earlier reportsnormal: 2.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 3.1M shares sold short in the 31 Jan 2025 report, 6.0× the same report last year.
Same report last year: 522K; its normal report is 707K.
See the evidence
This period
3.1M (the 31 Jan 2025 report)
Normal report (median of 24 earlier)
707K
Typical spread (median absolute deviation)
194K
How far from its usual level
+8.5
Same report last year
522K
History used
1,584 days
the 31 Jan 2025 report24 earlier reportsnormal: 707K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 3.1M shares sold short in the 15 Jan 2025 report, 6.9× the same report last year.
Same report last year: 451K; its normal report is 637K.
See the evidence
This period
3.1M (the 15 Jan 2025 report)
Normal report (median of 24 earlier)
637K
Typical spread (median absolute deviation)
134K
How far from its usual level
+12.5
Same report last year
451K
History used
1,568 days
the 15 Jan 2025 report24 earlier reportsnormal: 637K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 3.4M shares sold short in the 31 Dec 2024 report, 7.6× the same report last year.
Same report last year: 447K; its normal report is 626K.
See the evidence
This period
3.4M (the 31 Dec 2024 report)
Normal report (median of 24 earlier)
626K
Typical spread (median absolute deviation)
134K
How far from its usual level
+13.9
Same report last year
447K
History used
1,553 days
the 31 Dec 2024 report24 earlier reportsnormal: 626K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 3 insiders buy $208K of its shares on the open market within 30 days (3 filings), while it had 3.1M shares sold short in the 31 Jan 2025 report, 6.0× the same report last year. Two unrelated kinds of activity within 77 days.
See the evidence (7 changes)
Short interest and volume: Short interest spike became public on 27 Nov 2024
Prelude Therapeutics had 2.9M shares sold short in the 15 Nov 2024 report, 3.6× the same report last year.
This period
2.9M (the 15 Nov 2024 report)
Normal report (median of 24 earlier)
626K
Typical spread (median absolute deviation)
109K
How far from its usual level
+14.0
Same report last year
804K
History used
1,507 days
the 15 Nov 2024 report24 earlier reportsnormal: 626K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 11 Dec 2024
Prelude Therapeutics had 3.1M shares sold short in the 29 Nov 2024 report, 4.1× the same report last year.
This period
3.1M (the 29 Nov 2024 report)
Normal report (median of 24 earlier)
626K
Typical spread (median absolute deviation)
109K
How far from its usual level
+15.0
Same report last year
741K
History used
1,521 days
the 29 Nov 2024 report24 earlier reportsnormal: 626K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.
Short interest and volume: Short interest spike became public on 25 Dec 2024
Prelude Therapeutics had 3.3M shares sold short in the 13 Dec 2024 report, 4.8× the same report last year.
This period
3.3M (the 13 Dec 2024 report)
Normal report (median of 24 earlier)
626K
Typical spread (median absolute deviation)
113K
How far from its usual level
+15.7
Same report last year
680K
History used
1,535 days
the 13 Dec 2024 report24 earlier reportsnormal: 626K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 14 Jan 2025
Prelude Therapeutics had 3.4M shares sold short in the 31 Dec 2024 report, 7.6× the same report last year.
This period
3.4M (the 31 Dec 2024 report)
Normal report (median of 24 earlier)
626K
Typical spread (median absolute deviation)
134K
How far from its usual level
+13.9
Same report last year
447K
History used
1,553 days
the 31 Dec 2024 report24 earlier reportsnormal: 626K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 28 Jan 2025
Prelude Therapeutics had 3.1M shares sold short in the 15 Jan 2025 report, 6.9× the same report last year.
This period
3.1M (the 15 Jan 2025 report)
Normal report (median of 24 earlier)
637K
Typical spread (median absolute deviation)
134K
How far from its usual level
+12.5
Same report last year
451K
History used
1,568 days
the 15 Jan 2025 report24 earlier reportsnormal: 637K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 12 Feb 2025
Prelude Therapeutics had 3.1M shares sold short in the 31 Jan 2025 report, 6.0× the same report last year.
This period
3.1M (the 31 Jan 2025 report)
Normal report (median of 24 earlier)
707K
Typical spread (median absolute deviation)
194K
How far from its usual level
+8.5
Same report last year
522K
History used
1,584 days
the 31 Jan 2025 report24 earlier reportsnormal: 707K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
27 Dec 2024Insiders change
had 3 insiders buy $208K of its shares on the open market within 30 days (3 filings).
Who bought: Vaddi Krishna, Lim Bryant David, Combs Andrew.
Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.
had 3.3M shares sold short in the 13 Dec 2024 report, 4.8× the same report last year.
Same report last year: 680K; its normal report is 626K.
See the evidence
This period
3.3M (the 13 Dec 2024 report)
Normal report (median of 24 earlier)
626K
Typical spread (median absolute deviation)
113K
How far from its usual level
+15.7
Same report last year
680K
History used
1,535 days
the 13 Dec 2024 report24 earlier reportsnormal: 626K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 3.1M shares sold short in the 29 Nov 2024 report, 4.1× the same report last year.
Same report last year: 741K; its normal report is 626K.
See the evidence
This period
3.1M (the 29 Nov 2024 report)
Normal report (median of 24 earlier)
626K
Typical spread (median absolute deviation)
109K
How far from its usual level
+15.0
Same report last year
741K
History used
1,521 days
the 29 Nov 2024 report24 earlier reportsnormal: 626K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 2.9M shares sold short in the 15 Nov 2024 report, 3.6× the same report last year.
Same report last year: 804K; its normal report is 626K.
See the evidence
This period
2.9M (the 15 Nov 2024 report)
Normal report (median of 24 earlier)
626K
Typical spread (median absolute deviation)
109K
How far from its usual level
+14.0
Same report last year
804K
History used
1,507 days
the 15 Nov 2024 report24 earlier reportsnormal: 626K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 2.9M shares sold short in the 31 Oct 2024 report, 3.7× the same report last year.
Same report last year: 800K; its normal report is 626K.
See the evidence
This period
2.9M (the 31 Oct 2024 report)
Normal report (median of 24 earlier)
626K
Typical spread (median absolute deviation)
109K
How far from its usual level
+14.3
Same report last year
800K
History used
1,492 days
the 31 Oct 2024 report24 earlier reportsnormal: 626K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 2.5M shares sold short in the 15 Oct 2024 report, 3.1× the same report last year.
Same report last year: 799K; its normal report is 626K.
See the evidence
This period
2.5M (the 15 Oct 2024 report)
Normal report (median of 24 earlier)
626K
Typical spread (median absolute deviation)
109K
How far from its usual level
+11.5
Same report last year
799K
History used
1,476 days
the 15 Oct 2024 report24 earlier reportsnormal: 626K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 2.5M shares sold short in the 30 Sep 2024 report, 1.3× the same report last year.
Same report last year: 1.9M; its normal report is 626K.
See the evidence
This period
2.5M (the 30 Sep 2024 report)
Normal report (median of 24 earlier)
626K
Typical spread (median absolute deviation)
109K
How far from its usual level
+11.5
Same report last year
1.9M
History used
1,461 days
the 30 Sep 2024 report24 earlier reportsnormal: 626K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 3.3M shares sold short in the 13 Sep 2024 report, 1.9× the same report last year.
Same report last year: 1.7M; its normal report is 626K.
See the evidence
This period
3.3M (the 13 Sep 2024 report)
Normal report (median of 24 earlier)
626K
Typical spread (median absolute deviation)
109K
How far from its usual level
+16.7
Same report last year
1.7M
History used
1,444 days
the 13 Sep 2024 report24 earlier reportsnormal: 626K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 2.4M shares sold short in the 30 Aug 2024 report, 1.4× the same report last year.
Same report last year: 1.7M; its normal report is 626K.
See the evidence
This period
2.4M (the 30 Aug 2024 report)
Normal report (median of 24 earlier)
626K
Typical spread (median absolute deviation)
109K
How far from its usual level
+11.1
Same report last year
1.7M
History used
1,430 days
the 30 Aug 2024 report24 earlier reportsnormal: 626K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 1.4M shares sold short in the 15 Aug 2024 report, 33% below the same report last year.
Same report last year: 2.1M; its normal report is 626K.
See the evidence
This period
1.4M (the 15 Aug 2024 report)
Normal report (median of 24 earlier)
626K
Typical spread (median absolute deviation)
109K
How far from its usual level
+5.0
Same report last year
2.1M
History used
1,415 days
the 15 Aug 2024 report24 earlier reportsnormal: 626K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Showing the newest 40 of 77 entries; narrow the window or the kind of data to see older ones.
Not listed: 98 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.
Identifiers and sources
How records are matched to this company, and what each source holds for it
Cik
0001678660
Ticker
PRLD
Domain
preludetx.com
Employer name
PRELUDE THERAPEUTICS, INC. (1 unverified)
Hq location
DE|WILMINGTON|19805 (1 unverified)
Name
Prelude Therapeutics Incorporated
DOL H-1B labor condition applications and PERM certifications42 data points24 Feb 2020 to 24 Mar 2025
SEC Form 13F institutional holdings1 record, 225 data points30 Sep 2020 to 30 Sep 2026
SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)92 records11 Jul 2016 to 16 Nov 2026
SEC XBRL company facts (revenue, capex, R&D, backlog...)413 data points31 Dec 2018 to 11 Nov 2026
SEC Form 4 insider transactions57 records, 156 data points29 Sep 2020 to 23 Apr 2026
FINRA short interest (twice monthly)437 data points30 Sep 2020 to 30 Oct 2026
FINRA daily short sale volume (off-exchange)3094 data points25 Sep 2020 to 20 Nov 2026